Gilead SciencesFRA:GIS -1.34%75 FCF Margin % is 34.87% as of Mar. 2026, which is 0% above its 10-year median of 34.82. GuruFocus rates FRA:GIS with a GF Score™ of 75/100 and a GF Value™ of €82.28 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 958 Drug Manufacturers companies, Gilead Sciences ranks better than 97.39% on this metric.
The historical rank and industry rank for Gilead Sciences's FCF Margin % or its related term are showing as below:
FRA:GIS'
s FCF Margin % Range Over the Past 10 Years
Min: 27.37 Med: 34.82 Max: 53.63
Current: 34.31
During the past 13 years, the highest FCF Margin % of Gilead Sciences was 53.63%. The lowest was 27.37%. And the median was 34.82%.
FRA:GIS's FCF Margin % is ranked better than 97.39% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.445
vs FRA:GIS: 34.31
Gilead Sciences FCF Margin % Related Terms
Gilead Sciences FCF Margin % Historical Data
* Premium members only.
The historical data trend for Gilead Sciences's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:GIS vs AMGN, PFE, BMY: FCF Margin % Comparison
For the Drug Manufacturers - General subindustry, Gilead Sciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gilead Sciences FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Gilead Sciences's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gilead Sciences (FRA:GIS) has a FCF Margin % of 34.87% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Gilead Sciences and its competitors. This is near median its historical median of 34.82. Over the past decade, Gilead Sciences' FCF Margin % has ranged from 27.37 to 53.63. According to the industry distribution chart, Gilead Sciences ranks #25 out of 958 companies in the Drug Manufacturers industry, placing it in the top 2.6%.
Is Gilead Sciences' FCF Margin % too high?
Gilead Sciences' current FCF Margin % of 34.87% is near median its 10-year median of 34.82. Over the past 10 years, this metric has ranged from a low of 27.37 to a high of 53.63. The Drug Manufacturers industry median FCF Margin % is 2.45. Gilead Sciences' value of 34.87% is 1326.2% above this industry median. Based on the distribution chart, Gilead Sciences ranks #25 out of 958 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Gilead Sciences has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gilead Sciences' FCF Margin % compare to AMGN and PFE?
According to the Drug Manufacturers industry distribution chart, Gilead Sciences ranks #25 out of 958 companies for FCF Margin %. This places Gilead Sciences in the top 3% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 2.45. Gilead Sciences' value of 34.87% is 1326.2% above this benchmark. Historically, Gilead Sciences' own FCF Margin % has ranged from 27.37 to 53.63 over the past decade. While the company's 10-year median is 34.82 vs. the industry median of 2.45, Gilead Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gilead Sciences's current FCF Margin % of 34.87% is 1326.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Gilead Sciences and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gilead Sciences's current FCF Margin % is 34.87%, which is near median its own 10-year median of 34.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gilead Sciences stock overvalued right now?
Based on GuruFocus' analysis, Gilead Sciences (FRA:GIS) is currently considered Significantly Overvalued. The stock's GF Value™ is €82.28, compared to a current price of €109.12 — trading 32.6% above its estimated fair value. The current FCF Margin % is 34.87%, which is near median its 10-year median of 34.82 and 1326.2% above the Drug Manufacturers industry median of 2.45. Gilead Sciences' overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Gilead Sciences (FRA:GIS), the current FCF Margin % is 34.87% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gilead Sciences (FRA:GIS) Overvalued in 2026?
Based on GuruFocus' analysis, Gilead Sciences stock appears to be overvalued.
The current stock price of €109.12 is trading 32.6% above its estimated GF Value™ of €82.28.
GuruFocus considers Gilead Sciences to be Significantly Overvalued.
Key valuation signals for FRA:GIS:
FCF Margin %: 34.87% (near median its 10-year median of 34.82)
GF Value™: €82.28 vs. price of €109.12 (32.6% above fair value)
Industry Position: 1326.2% above the Drug Manufacturers median (#25 of 958)
No single metric tells the full story. See the FRA:GIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
75GF Score
Get the complete analysis for FRA:GIS
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:GIS has been successfully added to your 
